Evidence map›Paper›PMID 37575354›Full record

ArticleJournal of clinical medicine research2023

Radiologic Features of T10 Paravertebral Muscle Sarcopenia: Prognostic Factors in COVID-19.

Georgios Schinas, Vasiliki Dimakopoulou, Konstantinos Dionysopoulos, Georgia Fezoulidi, Marianna Vlychou, Katerina Vassiou, Nikolaos K Gatselis, Anna Samakidou, Georgios Giannoulis, Argyrios Tzouvelekis and 5 more

Open access · diamondAbstract read
In one paragraph

Article in Journal of clinical medicine research, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
1.2field-weighted citation impact, top 21% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 7 citations in OpenAlex.

  1. Observational
  2. Article
  3. Article
  4. Sarcopenia in interstitial lung disease.European respiratory review : an official journal of the European Respiratory Society · 2024
    Review
  5. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

15 authors at 5 institutions in 1 country.

Georgios SchinasSchool of Medicine, University of Patras, Patras, Greece.
Vasiliki DimakopoulouDepartment of Internal Medicine, University Hospital of Patras, Patras, Greece.
Konstantinos DionysopoulosDepartment of Radiology, University Hospital of Patras, Patras, Greece.
Georgia FezoulidiFaculty of Medicine, University of Thrace, Alexandroupolis, Greece.
Marianna VlychouDepartment of Radiology, General University Hospital of Larissa, Larissa, Greece.
Katerina VassiouDepartment of Anatomy, Medical School, University of Thessaly, Larisa, Greece.
Nikolaos K GatselisDepartment of Medicine and Research Laboratory of Internal Medicine, Expertise Center of Greece in Autoimmune Liver Diseases, European Reference Network on Hepatological Diseases (ERN RARE-LIVER), General University Hospital of Larissa, Larissa, Greece.
Anna SamakidouDepartment of Medicine and Research Laboratory of Internal Medicine, Expertise Center of Greece in Autoimmune Liver Diseases, European Reference Network on Hepatological Diseases (ERN RARE-LIVER), General University Hospital of Larissa, Larissa, Greece.
Georgios GiannoulisDepartment of Medicine and Research Laboratory of Internal Medicine, Expertise Center of Greece in Autoimmune Liver Diseases, European Reference Network on Hepatological Diseases (ERN RARE-LIVER), General University Hospital of Larissa, Larissa, Greece.
Argyrios TzouvelekisDivision of Respiratory Medicine, Department of Internal Medicine, University Hospital of Patras, Patras, Greece.
Markos MarangosDivision of Infectious Diseases, Department of Internal Medicine, University Hospital of Patras, Patras, Greece.
Charalambos GogosDivision of Infectious Diseases, Department of Internal Medicine, University Hospital of Patras, Patras, Greece.
George N DalekosDepartment of Medicine and Research Laboratory of Internal Medicine, Expertise Center of Greece in Autoimmune Liver Diseases, European Reference Network on Hepatological Diseases (ERN RARE-LIVER), General University Hospital of Larissa, Larissa, Greece.
Christina KalogeropoulouDepartment of Radiology, University Hospital of Patras, Patras, Greece.
Karolina AkinosoglouDivision of Infectious Diseases, Department of Internal Medicine, University Hospital of Patras, Patras, Greece.
General University Hospital of Patras · GRUniversity Hospital of Larissa · GRUniversity Hospital of Alexandroupolis · GRUniversity of Patras · GRUniversity of Thessaly · GR

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background: Sarcopenia, defined as a small cross-sectional area (CSA) in computed tomography (CT) measurements of skeletal muscles, serves as a disease severity marker in various clinical scenarios, including pulmonary conditions and critical illness. Another parameter of sarcopenia, the level of myosteatosis, reflected by the tissue's radiodensity, in the thoracic skeletal muscles group, has been linked to disease progression in coronavirus disease 2019 (COVID-19) patients. We hypothesize that CT-derived measurements of the skeletal muscle density (SMD) and the CSA of thoracic skeletal muscles can predict outcomes in COVID-19 pneumonia. Methods: We retrospectively reviewed the CT scans of 84 patients with COVID-19 pneumonia admitted to two of Greece's largest academic teaching hospitals between April 2020 and February 2021. CSA and SMD at the level of the T10 vertebra were measured using computational imaging methods. The patient population was stratified according to survival status and CT severity score (CT-SS). Correlations were drawn between the radiologic features of sarcopenia, CT severity subgroups, serum inflammatory markers, and adverse events, e.g., death and intubation. Results: Thoracic muscles' CSA measurements correlate with CT-SS and prominent inflammatory markers, such as white blood cell (WBC), C-reactive protein (CRP), fibrinogen, and D-dimers. Moreover, according to linear regression analysis, CSA seems to predict CT-SS variation significantly (β = -0.266, P = 0.018). CSA proved to differ significantly across survivors (P = 0.027) but not between CT severity categories and intubation subgroups. The AUC (area under the curve) of the receiver operating characteristic (ROC) curve for the predictive value of thoracic muscles' CSA in mortality is 0.774 (95% confidence interval (CI): 0.66 - 0.83, P < 0.000). The optimal cut-off value (Youden index = 0.57) for mortality prognosis, with a sensitivity of 66.7% and a specificity of 88.9%, is 15.55. Thoracic muscles' SMD analyses did not reveal any significant correlations. Conclusions: Easy to obtain and accurately calculated, radiologic features can provide a reliable alternative to laboratory methods for predicting survival in COVID-19. Thoracic muscles' CSA measurement in the level of the T10 vertebra, an acclaimed prognostic imaging assessment that relates directly to CT-SS and inflammatory markers in COVID-19 pneumonia, is a fairly specific tool for survival prognosis.

Indexed as

Chest computed tomographyCOVID-19Cross-sectional anatomyMuscle massPrognostic factorsSAR-CoV-2

Identifiers

PMID37575354
PMCPMC10416190
OpenAlexW4385464300

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.